X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA FULFORD INDIA ALEMBIC PHARMA/
FULFORD INDIA
 
P/E (TTM) x 26.6 398.8 6.7% View Chart
P/BV x 5.4 6.2 86.3% View Chart
Dividend Yield % 0.6 0.1 747.4%  

Financials

 ALEMBIC PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
FULFORD INDIA
Mar-14
ALEMBIC PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs645942 68.5%   
Low Rs470450 104.4%   
Sales per share (Unadj.) Rs166.1691.4 24.0%  
Earnings per share (Unadj.) Rs21.911.5 191.1%  
Cash flow per share (Unadj.) Rs27.515.4 179.0%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.70.3 249.7%  
Book value per share (Unadj.) Rs117.8380.0 31.0%  
Shares outstanding (eoy) m188.523.90 4,833.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.0 333.4%   
Avg P/E ratio x25.560.7 41.9%  
P/CF ratio (eoy) x20.345.3 44.7%  
Price / Book Value ratio x4.71.8 258.4%  
Dividend payout %18.317.4 104.7%   
Avg Mkt Cap Rs m105,0902,714 3,871.6%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m6,228505 1,233.3%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m31,3082,696 1,161.1%  
Other income Rs m70125 56.1%   
Total revenues Rs m31,3782,822 1,112.0%   
Gross profit Rs m6,431-46 -13,859.7%  
Depreciation Rs m1,05515 6,938.2%   
Interest Rs m3410 357.9%   
Profit before tax Rs m5,41354 9,968.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-810-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,20410 12,536.5%   
Profit after tax Rs m4,12845 9,235.3%  
Gross profit margin %20.5-1.7 -1,193.7%  
Effective tax rate %22.217.7 125.8%   
Net profit margin %13.21.7 795.4%  
BALANCE SHEET DATA
Current assets Rs m18,2471,738 1,049.7%   
Current liabilities Rs m11,235545 2,062.6%   
Net working cap to sales %22.444.3 50.6%  
Current ratio x1.63.2 50.9%  
Inventory Days Days8648 176.6%  
Debtors Days Days614 1,425.5%  
Net fixed assets Rs m20,03512 168,363.9%   
Share capital Rs m37739 966.7%   
"Free" reserves Rs m21,8241,443 1,512.4%   
Net worth Rs m22,2011,482 1,498.1%   
Long term debt Rs m5,0000-   
Total assets Rs m39,4112,077 1,897.7%  
Interest coverage x160.26.7 2,385.3%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.81.3 61.2%   
Return on assets %10.62.6 404.7%  
Return on equity %18.63.0 616.5%  
Return on capital %19.74.3 458.2%  
Exports to sales %46.40-   
Imports to sales %10.524.5 43.0%   
Exports (fob) Rs m14,535NA-   
Imports (cif) Rs m3,288659 498.8%   
Fx inflow Rs m14,72217 85,590.7%   
Fx outflow Rs m7,026673 1,043.7%   
Net fx Rs m7,696-656 -1,173.2%   
CASH FLOW
From Operations Rs m3,12490 3,471.3%  
From Investments Rs m-8,844105 -8,454.9%  
From Financial Activity Rs m5,026-14 -35,647.5%  
Net Cashflow Rs m-693181 -384.1%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 3.8 76.3%  
FIIs % 9.1 0.1 9,100.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 21.2 65.6%  
Shareholders   49,328 4,783 1,031.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   JUBILANT LIFE SCIENCES  PLETHICO PHARMA  WOCKHARDT LTD.  ABBOTT INDIA  AUROBINDO PHARMA  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 18, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS